AstraZeneca beat expectations for third quarter earnings on Thursday with strong sales of its blockbuster cancer and ...

The latest investor updates on stocks that are trending on Thursday.

COVID-19 vaccine would continue despite many European nations pausing vaccination to investigate serious side effects ...

AstraZeneca's chief executive officer Pascal Soriot said on Monday that the lower first dose of its experimental COVID-19 ...

AstraZeneca beat third-quarter earnings expectations on Thursday, helped by strong sales of its cancer, heart and kidney ...

European stocks opened lower on Thursday as investors processed another heavy slate of corporate earnings reports, with ...

CAMBRIDGE, Britain (AP) — CAMBRIDGE, Britain (AP) — Astrazeneca PLC (AZN) on Thursday reported third-quarter net income of $2.53 billion. On a per-share basis, the Cambridge, Britain-based company ...

AstraZeneca ( AZN) posted stronger-than-expected Q3 results, fueled by continued strength in its oncology portfolio. The U.K.

AstraZeneca's revenue grew in the third quarter, boosted by the strength of the company's treatments pipeline. "AstraZeneca Revenue Climbs on Pipeline Strength, U.S. Price Deal," at 0725 GMT, ...

In the third quarter, Oncology revenue rose 18% to USD6.64 billion, Cardiovascular, Renal & Metabolism sales were flat at USD3.22 billion, R&I grew 14% to USD2.26 billion, BioPharmaceuticals firmed 4% ...

AstraZeneca CEO Pascal Soriot discusses Q3 earnings and the pharma giant's relationship with the U.S. administration.

The pharmaceutical company posted a 14% on-year increase in third-quarter core earnings per share, while revenue rose to ...